MEDADVISOR LIMITED (MDR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MDR

MDR - MEDADVISOR LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.83
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.092

15 Apr
2025

0.002

OPEN

$0.09

2.22%

HIGH

$0.09

667,997

LOW

$0.09

TARGET
$0.09 -2.2% downside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
MDR: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 0.1 - 1.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx122.1 M
Book Value Per Share xxxxxxxxxxxxxxx9.4
Net Operating Cash Flow xxxxxxxxxxxxxxx5.2 M
Net Profit Margin xxxxxxxxxxxxxxx0.65 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx1.58 %
Return on Invested Capital xxxxxxxxxxxxxxx1.41 %
Return on Assets xxxxxxxxxxxxxxx0.81 %
Return on Equity xxxxxxxxxxxxxxx1.58 %
Return on Total Capital xxxxxxxxxxxxxxx4.29 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx5.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx13 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx13 M
Goodwill - Gross xxxxxxxxxxxxxxx46 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx16 M
Price To Book Value xxxxxxxxxxxxxxx5.34

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1.8 M
Capex % of Sales xxxxxxxxxxxxxxx1.50 %
Cost of Goods Sold xxxxxxxxxxxxxxx98 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx21 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

03/04/2025

3

Hold

$0.09

-2.17%

Bell Potter highlights the $5m placement and $2m share purchase plan at 10c per share for MedAdvisor, with the new equity issued representing between 9%–15% of shares on issue.

The funds raised will be employed for working capital and cost-out plans, the broker explains, as cash on hand had fallen to $12.4m at the end of December 31 and debt had risen to $17.6m.

Board changes with the resignation of Chair, Linda Jackson, and the appointment of non-executive Director Kate Hill as interim Chair have raised a "red flag" according to the analyst.

Management also offered weaker FY25 guidance due to deteriorating business conditions. Unchanged Hold rating and target price cut to 9c from 21c.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.90 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

10/03/2025

3

Downgrade to Hold from Buy

$0.19

106.52%

Canaccord Genuity notes MedAdvisor's -24% y/y 1H25 revenue decline was pre-reported but the EBITDA beat didn't translate to higher cash flow.

The revenue decline was attributed to several factors and while the company showed conviction about improvement, the broker isn't confident about customer and pipeline conversion.

The broker would like to see a sustainable pathway to revenue growth, combined with the positive impact of Transformation 360.

The analyst lowered near-term revenue and earnings outlook. Target price cut to 19c (was 57c in November).

Rating downgraded to Hold from Buy.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
Access Extra Coverage Research History >

MDR STOCK CHART

FNArena News on MDR

1
Australian Broker Call *Extra* Edition – Apr 07, 2025

Apr 07 2025 - Daily Market Reports
2
In Case You Missed It – BC Extra Upgrades & Downgrades – 14-03-25

Mar 14 2025 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Mar 10, 2025

Mar 10 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Mar 05, 2025

Mar 05 2025 - Daily Market Reports
5
In Case You Missed It – BC Extra Upgrades & Downgrades – 07-02-25

Feb 07 2025 - Weekly Reports

Latest Healthcare services News

1
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
2
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
3
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
4
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
5
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
6
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
7
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
8
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
9
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
10
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps